In summary, PTPN22 does not directly regulate the growth or proliferation of tumor cells; rather, it promotes tumor progression by modulating PD-L1 expression, which in turn alters T cell infiltration within the tumor immune microenvironment. Here, CD274 is linked to neoplasm.